Mount Sinai Study Reveals New Genetic Link to Heart Disease
Findings may help improve risk prediction tools for cardiovascular disease
How "environmentally triggered" genetic variants of cellular gene networks contribute to heart disease heritability. (A) Schematics of the macro- and micro levels of gene-environmental interactions. Macro-environmental factors (e.g., lifestyle, food intake and smoking) interact with genetic variants in organs to change the micro-environment in cellular networks leading to heart disease.
A collaboration involving the Icahn School of Medicine at Mount Sinai, the German Heart Center Munich, AstraZeneca, and Karolinska Institutet in Sweden has demonstrated that more than 30 percent of heart disease risk stems from genetic factors, much more than was previously understood. The study findings, published June 18th in the Journal of the American College of Cardiology, introduce the biology of gene networks as means to better understand the heritability and genetic underpinnings of heart disease.
Coronary artery disease (CAD), the most common type of heart disease and one of the leading causes of death worldwide, forms plaque in the walls of the arteries that supply blood to the heart. A complete blockage of these arteries can lead to a heart attack or stroke.
Before this study, more than a decade of genome-wide-association studies (GWAS)—the analysis of genetic risk codes found more frequently in people with a particular trait, such as heart disease—had indicated that less than a quarter of CAD was considered inheritable. Meanwhile, the heritability contribution (if any) of genetic variants in gene regulatory networks (GRNs)—a set of genes that interact with each other to control a particular cell function—was unknown. In light of this, researchers used tissue data from two separate studies of individuals with CAD to determine whether genetic variants that regulate GRNs make independent contributions to the risk of heart disease.
Across vascular and metabolic tissue data, researchers identified and replicated 28 independent GRNs active in CAD and determined that the genetic variation in these networks contributed to the inherited risk of the heart disease by an additional 11 percent—adding to the 22 percent attributable risk previously identified by GWAS. This newfound contribution boosts the heritability of CAD to approximately 32 percent, spotlighting the important role played by interactions between internal environments and genetic variants—mediated by regulatory networks—in the development of heart disease.
“The results of this study demonstrate that the risk of heart disease is a concerted result of interactions between genetic variants and biological environments,” said Johan LM Björkegren, Professor of Medicine (Cardiology), and Genetics, at the Icahn School of Medicine at Mount Sinai. “By understanding the complex relationship between the two, we’ve created a framework for identifying new risk genes in disease-relevant tissues leading to heart disease, which in turn will allow for more effective risk prediction, clinical intervention, and eventually, opportunities for novel and more effective therapies.”
Another researcher involved in the study, Heribert Schunkert, MD, Professor of Cardiology at the German Heart Center in Munich, added, “A mystery of recent research was the fact that many genes contributing to the genetics of coronary artery disease affect mechanisms that were not expected in this context. The present study leads to a much better understanding of how these genes work together in precipitating or preventing the disease.”
Li-Ming Gan, Vice President of Early Clinical Development, Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals, AstraZeneca, commented that this study “provides new insight into the heritability of coronary artery disease, adding a substantial number of genetic variants contributing to its heritability. Further analysis may help explain the disease’s etiology and give novel insights on how to prevent its development.”
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.
Targeting One Type of Immune Cell With Another Slows Cancer Growth in Preclinical Studies
Oct 25, 2022 View All Press Releases
Novel CRISPR Imaging Technology Reveals Genes Controlling Tumor Immunity
Mar 15, 2022 View All Press ReleasesMount Sinai Researchers: Why COVID-19 May Be Less Common in Children Than Adults
May 22, 2020 View All Press ReleasesAirway Microbiome and Host Interact Differently in Children with Severe Asthma
Mar 12, 2020 View All Press Releases